Key Facts
• June 30, 2025: ACCESS disclosed investigation results by external lawyers.
• $41 million in inflated profits over 8 years (up to January 2025).
• U.S.-based subsidiary IP Infusion (IPI) involved in accounting fraud.
• Fraud methods: fake product shipments, misclassified software development costs.
• Two ACCESS executives resigned due to involvement in the scheme.
• Inflated profits reflected in ACCESS’s consolidated financial statements.
Summary
Software developer ACCESS, listed on the Tokyo Stock Exchange Prime, revealed that its U.S.-based subsidiary, IP Infusion (IPI), inflated profits by approximately $41 million over eight years. The fraudulent practices included recording fake product shipments as revenue and misclassifying software development costs as assets. These actions impacted ACCESS’s consolidated financial statements. Following an external investigation, two executives involved in the scheme resigned. The company has since disclosed the findings, highlighting the scale of the accounting irregularities.
